Intercept Pharmaceuticals, Inc. (ICPT) |
|
13.67 0.67 (5.15%)
|
06-29 17:15 |
|
Open: |
13.02 |
Pre. Close: |
13 |
|
High:
|
13.7 |
Low:
|
12.86 |
|
Volume:
|
349,804 |
Market Cap:
|
406(M) |
|
|
|
|
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
13.71 - 13.77 |
13.77 - 13.84 |
|
Low:
|
12.71 - 12.77 |
12.77 - 12.84 |
|
Close:
|
13.56 - 13.67 |
13.67 - 13.78 |
|
Technical analysis |
as of: 2022-06-29 4:54:44 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 18.41 One year: 21.99 |
| Support: |
Support1: 10.81 Support2: 8.99 |
| Resistance: |
Resistance1: 15.76 Resistance2: 18.82 |
| Pivot: |
12.62  |
| Moving Average: |
MA(5): 13.44  MA(20): 13.32
MA(100): 15.79 MA(250): 16.08 |
| MACD: |
MACD(12,26): -0.9 Signal(9): -1.1 |
| Stochastic oscillator: |
%K(14,3): 71.2 %D(3): 59.8 |
| RSI: |
RSI(14): 46.6 |
| 52-week: |
High: 20.5 Low: 10.81 |
| Average Vol(K): |
3-Month: 964 (K) 10-Days: 672 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ICPT ] has closed below upper band by 15.4%. Bollinger Bands are 21.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 29 Jun 2022
Why did Arrowhead Pharmaceuticals stock pop up today? - Seeking Alpha
Wed, 29 Jun 2022
Impact Clean Power Technology builds plant in Poland - electrive.com - www.electrive.com
Wed, 29 Jun 2022
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions - Digital Journal
Tue, 28 Jun 2022
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Tue, 28 Jun 2022
TNB should diversify gas, coal sources, say analysts - Free Malaysia Today
Mon, 27 Jun 2022
ICPT concerns may resurface given the high coal prices - The Star Online
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
30 (M) |
| Shares Float |
25 (M) |
|
% Held by Insiders
|
4.3 (%) |
|
% Held by Institutions
|
101.5 (%) |
|
Shares Short
|
7,990 (K) |
|
Shares Short P.Month
|
8,240 (K) |
Stock Financials |
|
EPS
|
-3.28 |
|
EPS Est Next Qtl
|
-3.45 |
|
EPS Est This Year
|
-13.99 |
|
EPS Est Next Year
|
-11.6 |
|
Book Value (p.s.)
|
-5.29 |
|
Profit Margin (%)
|
-25.2 |
|
Operating Margin (%)
|
-15.4 |
|
Return on Assets (ttm)
|
-6.3 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
11 |
|
Gross Profit (p.s.)
|
12.19 |
|
Sales Per Share
|
12.3 |
|
EBITDA (p.s.)
|
-1.79 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-42 (M) |
|
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
|
PE Ratio
|
-4.17 |
|
PEG Ratio
|
-3.8 |
|
Price to Book value
|
-2.59 |
|
Price to Sales
|
1.11 |
|
Price to Cash Flow
|
-9.71 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
